Squarepoint Ops LLC Revance Therapeutics, Inc. Transaction History

Squarepoint Ops LLC

$62.8 Billion
Q3 2024

A detailed history of Squarepoint Ops LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 2,309,662 shares of RVNC stock, worth $5.94 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,309,662

Holding current value

$5.94 Million

% of portfolio

0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.57 - $2.57 $5.94 Million - $5.94 Million	2,309,662 New	2,309,662 $5.94 Million
Q2 2023 Aug 14, 2023	SELL	$24.7 - $37.61 $1.41 Million - $2.14 Million	-57,023 Reduced 63.91%	32,206 $815,000
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $58,164 - $111,735	3,168 Added 3.68%	89,229 $2.87 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $1.23 Million - $2.06 Million	67,310 Added 358.97%	86,061 $1.59 Million
Q3 2022 Nov 14, 2022	SELL	$14.33 - $28.47 $218,575 - $434,252	-15,253 Reduced 44.86%	18,751 $506,000
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $4,112 - $7,282	357 Added 1.06%	34,004 $470,000
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $415,876 - $683,370	33,647 New	33,647 $656,000
Q3 2021 Nov 15, 2021	SELL	$25.78 - $33.21 $785,336 - $1.01 Million	-30,463 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$26.8 - $31.84 $546,612 - $649,408	20,396 Added 202.6%	30,463 $903,000
Q1 2021 May 17, 2021	BUY	$24.03 - $29.97 $241,910 - $301,707	10,067 New	10,067 $281,000
Q4 2020 Feb 16, 2021	SELL	$23.41 - $28.34 $560,575 - $678,629	-23,946 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$23.23 - $34.3 $799,646 - $1.18 Million	-34,423 Reduced 58.97%	23,946 $602,000
Q2 2020 Aug 14, 2020	BUY	$12.6 - $26.55 $366,697 - $772,684	29,103 Added 99.44%	58,369 $1.43 Million
Q1 2020 May 15, 2020	SELL	$12.46 - $27.81 $175,362 - $391,397	-14,074 Reduced 32.47%	29,266 $433,000
Q4 2019 Feb 14, 2020	BUY	$11.66 - $20.15 $505,344 - $873,300	43,340 New	43,340 $703,000
Q3 2019 Nov 14, 2019	SELL	$10.22 - $14.5 $690,136 - $979,156	-67,528 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$10.67 - $15.49 $427,674 - $620,870	40,082 Added 146.04%	67,528 $876,000
Q1 2019 May 15, 2019	BUY	$15.4 - $20.39 $227,904 - $301,751	14,799 Added 117.02%	27,446 $433,000
Q4 2018 Feb 14, 2019	SELL	$18.06 - $24.96 $94,291 - $130,316	-5,221 Reduced 29.22%	12,647 $255,000
Q3 2018 Nov 14, 2018	BUY	$23.55 - $30.1 $420,791 - $537,826	17,868 New	17,868 $444,000
Q2 2018 Aug 14, 2018	SELL	$27.45 - $33.35 $470,218 - $571,285	-17,130 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$29.15 - $37.4 $439,028 - $563,281	-15,061 Reduced 46.79%	17,130 $528,000
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $790,289 - $1.17 Million	32,191	32,191 $1.15 Million

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Account

Squarepoint Ops LLC Revance Therapeutics, Inc. Transaction History